HGS/GSK On Track To Initiate Lymphostat-B Phase III Study In 2006
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Human Genome Sciences and its development partner GlaxoSmithKline are on track to initiate a Phase III study of LymphoStat-B for the treatment of systemic lupus erythematosus in 2006, HGS said.
You may also be interested in...
HGS LymphoStat-B to begin Phase III in Q4
Human Genome Sciences will begin a Phase III trial of LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus in the fourth quarter of 2006, the company announces Aug. 9. HGS expects a $24 mil. milestone payment from development partner GlaxoSmithKline in the third quarter. HGS collaborated with GSK to design the Phase III study, which has an endpoint that combines response rate and elements of the SELENA SLEDAI and BILAG disease activity indices, as well as the Physician's Global Assessment index. A Phase II study failed to show a clinical benefit at week 24, but HGS previously indicated its belief that the Phase II data are strong enough to move into Phase III studies (1Pharmaceutical Approvals Monthly July 2006, p. 16)...
HGS Refines LymphoStat-B Lupus Trial Design After Phase II Misses Endpoints
Human Genome Sciences believes it can move ahead with Phase III trials of its systemic lupus erythematosus therapy LymphoStat-B but will refine the clinical study design - including clinical endpoints - from that used in Phase II
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011